Proactive Research analyst Emma Ulker discusses MaxCyte’s () new clinical and commercial licence agreement with Caribou Biosciences.

She says the agreement which allows the use of its proprietary Flow Electroporation technology for Caribou’s CRISPR gene-edited allogeneic T-cell therapy programmes is the latest in a series of late-stage clinical and commercial collaborations in cell and gene therapy.

Click here to read Emma Ulker's latest update on Maxcyte

Source link